GLP-3R Explained: The Triple-Agonist Product Code and the Evidence

“GLP-3R” is not a molecule name you will find in a pharmacology textbook. It is a vendor product code. The naming convention is doing the work: in this shorthand, the number signals how many receptors are targeted (1 = mono-agonist, 2 = dual, 3 = triple) and the letter points to a reference compound — here, “R” for retatrutide. So GLP-3R is best read as a product sold under a code denoting a triple GIP/GLP-1/glucagon receptor agonist of the retatrutide class. It is not, on the label alone, proof of what is in the vial. The actual compound, dose, and purity must be confirmed against the product’s Certificate of Analysis (COA). With that framing fixed, the useful question is: what does the real retatrutide-class science actually show?

What a triple agonist is trying to do

Retatrutide (Eli Lilly’s LY3437943) is the archetype of this class: a single molecule that activates three receptors at once — GIP, GLP-1, and glucagon.

The first two receptors are familiar from tirzepatide: GLP-1 and GIP agonism curb appetite and improve insulin response. The third — glucagon receptor agonism — is the differentiator. Glucagon raises blood sugar, which sounds counterproductive, but it also increases energy expenditure and hepatic fat oxidation. The bet is a “two-sided” effect: reduce calories in via appetite suppression while nudging calories out via metabolic rate, with the GLP-1 component offsetting glucagon’s glucose-raising tendency.

In a 48-week phase 2 trial published in the New England Journal of Medicine (2023, n=338), retatrutide at 12 mg produced a mean weight reduction of 24.2%, versus 2.1% for placebo — but the compound remains investigational.

The phase 2 numbers

The trial, led by Ania M. Jastreboff, reported dose-dependent, least-squares mean weight change at 48 weeks:

Group	Mean weight change at 48 weeks
Placebo	−2.1%
Retatrutide 1 mg	−8.7%
Retatrutide 4 mg	−17.1%
Retatrutide 8 mg	−22.8%
Retatrutide 12 mg	−24.2%

These are among the largest weight-loss figures reported for any pharmacotherapy — but they come from a single phase 2 study. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), dose-related and mostly mild to moderate, and largely tied to dose escalation. The trial also noted dose-dependent heart-rate increases that peaked around 24 weeks.

Why the “GLP-3R” distinction matters

Retatrutide is not FDA approved. As of mid-2026 it is still investigational, with Lilly’s phase 3 TRIUMPH program active across obesity, type 2 diabetes, cardiovascular and kidney outcomes, and related conditions — active but not yet complete.

That matters directly for a grey-market vial sold as “GLP-3R.” Because retatrutide itself is an investigational-class compound with no approved, quality-controlled supply, a vial bought under a vendor code is not the clinical drug. It carries the specific risks of any unregulated peptide: the identity may not match the label, purity and potency are unverified, and sterility is not guaranteed. The impressive trial numbers above describe a characterized molecule administered under medical supervision — they do not transfer to whatever is in an unlabeled vial.

The takeaway

The science behind the retatrutide class is real, genuinely promising, and phase 2 to early phase 3 in maturity. The product “GLP-3R” is a marketing code, not a guarantee that the science applies to what you receive. Treat the trial data as evidence about a drug still being tested, and treat any grey-market vial as an unapproved, unverified compound — confirm identity, dose, and purity via a COA, and understand that no COA makes an investigational agent a proven or approved therapy.

Sources

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al., NEJM, 2023)
• Retatrutide (LY3437943) Phase 3 TRIUMPH trials — ClinicalTrials.gov